诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688428 诺诚健华

已收盘 07-30 15:00:01

{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":30.3,"timestamp":1753858801000,"preClose":30.71,"halted":0,"volume":6589659,"delay":0,"changeRate":-0.0134,"floatShares":268000000,"shares":1764999999,"eps":-0.1589,"marketStatus":"已收盘","change":-0.41,"latestTime":"07-30 15:00:01","open":30.25,"high":31.48,"low":30.1,"amount":203000000,"amplitude":0.0449,"askPrice":30.32,"askSize":10,"bidPrice":30.3,"bidSize":190,"shortable":0,"etf":0,"ttmEps":-0.1589,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753925400000},"marketStatusCode":5,"adr":0,"adjPreClose":30.71,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":33.78,"lowLimit":27.64,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1764643952,"isCdr":false,"pbRate":7.92,"roa":"--","roe":"0.27%","epsLYR":-0.26,"committee":0.206186,"marketValue":53469000000,"turnoverRate":0.0246,"status":1,"afterMarket":{"amount":0,"volume":0,"close":30.3,"buyVolume":0,"sellVolume":0,"time":1753860838019,"indexStatus":"已收盘 07-30 15:30:00","preClose":30.71},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":18.24,"timestamp":1753862890009,"preClose":18.84,"halted":0,"volume":18545000,"delay":0,"premium":"-44.76"},"floatMarketCap":8131000000},"requestUrl":"/m/hq/s/688428","defaultTab":"news","newsList":[{"id":"2555035386","title":"港股收评：午后回升！恒指小幅下跌0.15%，创新药涨幅抢眼，三胎概念股高开低走","url":"https://stock-news.laohu8.com/highlight/detail?id=2555035386","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555035386?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:21","pubTimestamp":1753777290,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c07cc57ab6b694d79365e96e00510786","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02186","MIUmain","01093","601939","603259","688428","KSTmain","03086","HSImain","01801","BABA","01810","08496","TTTN","02359","688235","TCHmain","HHImain","06978","HTCD.SI","TCEHY","06160","MCHmain","09618","MHImain","HSCEI","09969","METmain","01024","HSI","ALBmain","01530","01288","00939","00700","601288","03690","161726","HSTECH","601398","MPNGY","BIDU","JD","399441","01398","YANG","ONC","159992","07226"],"gpt_icon":0},{"id":"2555846140","title":"诺诚健华-U涨5.05% 核心管线商业化进展推动估值重塑","url":"https://stock-news.laohu8.com/highlight/detail?id=2555846140","media":"智选洞察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555846140?lang=zh_cn&edition=full","pubTime":"2025-07-29 13:03","pubTimestamp":1753765406,"startTime":"0","endTime":"0","summary":"诺诚健华-U今日股价明显走强，截至13点02分，股价报31.39元/股，涨幅达5.05%，成功站上30元整数关口。资金分歧与估值博弈共振诺诚健华-U近期股价波动与资金面分歧密切相关。此外，创新药支持政策落地后部分资金选择兑现离场，7月22日至24日单日股价振幅最高达9.50%，市场情绪扰动进一步放大波动。核心管线商业化决定估值重塑长期来看，诺诚健华-U的估值锚点在于核心产品的商业化进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729130342a6c7223a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729130342a6c7223a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2553247496","title":"诺诚健华-U股价下跌4.25% 创新药板块获基金经理关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2553247496","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553247496?lang=zh_cn&edition=full","pubTime":"2025-07-24 03:25","pubTimestamp":1753298737,"startTime":"0","endTime":"0","summary":"截至2025年7月23日15时，诺诚健华-U股价报30.22元，较前一交易日下跌1.34元，跌幅4.25%。当日开盘价为31.15元，最高触及31.58元，最低下探至30.14元，成交量为8.65万手，成交额达2.66亿元。诺诚健华-U属于生物制品和创新药板块，专注于肿瘤及自身免疫性疾病领域的创新药物研发。部分基金经理在二季度加大了对创新药板块的配置。数据显示，诺诚健华-U当日主力资金净流出595.32万元，占流通市值的0.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724033050954f456d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724033050954f456d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159992","688428"],"gpt_icon":0},{"id":"2553575942","title":"券商资管系公募，排名来了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2553575942","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553575942?lang=zh_cn&edition=full","pubTime":"2025-07-23 00:06","pubTimestamp":1753200372,"startTime":"0","endTime":"0","summary":"头部券商资管公募管理规模普遍增长Wind数据显示，截至二季度末，共有4家券商资管机构的公募基金资产管理总规模超千亿元。此外，相比于今年一季度末，头部券商资管的公募管理规模普遍增长，东方红资产管理、华泰证券资管规模增长均超200亿元，招商证券资管规模增长33亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","688428","BK0239","06160","01276","ONC","688192","688235","688443","688266","600276","09969"],"gpt_icon":0},{"id":"2553839762","title":"化学制药行业盘中拉升，丽珠集团涨8.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553839762","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553839762?lang=zh_cn&edition=full","pubTime":"2025-07-22 10:00","pubTimestamp":1753149629,"startTime":"0","endTime":"0","summary":"07月22日，化学制药行业盘中拉升，截至10点00分，化学制药行业整体指数上涨1.01%，报13861.410点。从个股上来看，该行业的成分股中，丽珠集团涨8.75%，苑东生物、诺诚健华-U等8只股涨幅超过5%。从资金上来看，截止发稿，化学制药行业主力净流入为-1249.79万，其中ST诺泰受到资金热捧，主力净流入1.89亿；拉长时间线来看，该板块近20日主力资金净流入-84.09亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072210002997afbef1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072210002997afbef1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0187","BK0028","000513","688428","BK0239","BK0188"],"gpt_icon":0},{"id":"2553288748","title":"港股创新药板块异动拉升 丽珠医药涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553288748","media":"E公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553288748?lang=zh_cn&edition=full","pubTime":"2025-07-22 09:53","pubTimestamp":1753149192,"startTime":"0","endTime":"0","summary":"人民财讯7月22日电，港股创新药板块异动拉升，截至发稿，丽珠医药涨超12%，凯莱英涨超6%，诺诚健华涨超4%，君实生物涨超3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722095312a6b9724c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"689392912ea8b05968e2ae0b7e09d3f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722095312a6b9724c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01513","01877","BK1191","BK1161","06821","688180","BK1574","688428","HSCEI","06978","09969"],"gpt_icon":0},{"id":"2553008144","title":"公募基金2025年二季报全扫描【国信金工】","url":"https://stock-news.laohu8.com/highlight/detail?id=2553008144","media":"量化藏经阁","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553008144?lang=zh_cn&edition=full","pubTime":"2025-07-22 08:06","pubTimestamp":1753142805,"startTime":"0","endTime":"0","summary":"一基金仓位监控在跟踪基金仓位变化时，由于2015年四季度以前股票型基金仓位规定下限为60%，在这之后规定为80%。截至2025年二季报，科技类板块配置权重依旧最高，最新一期配置权重为37.42%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722082610a6b94be8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722082610a6b94be8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BYDDY","09988","BK4588","YANG","600519","09969","ONC","BK4099","03750","BK4585","688428","688235","BK4614","EVS.SI"],"gpt_icon":0},{"id":"2553842793","title":"葛兰、谢治宇最新持仓曝光：共同聚焦创新药，这些个股被重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2553842793","media":"每经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553842793?lang=zh_cn&edition=full","pubTime":"2025-07-21 16:56","pubTimestamp":1753088193,"startTime":"0","endTime":"0","summary":"另外，兴证全球基金谢治宇管理的兴全合润，二季度减持了比亚迪、海尔智家，转而重仓分众传媒、蓝思科技。葛兰二季度加码创新药先从中欧医疗健康来看，二季度虽然出现净赎回的情况，但整体份额依然超过185亿份，规模超过300亿元。整体来看，创新药行业的持仓个股数量进一步增加，而多只医疗个股、中药个股已不见身影。可以看出，谢治宇二季度也偏爱创新药，重仓了多只个股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721165943a459004f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721165943a459004f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BYDDY","BK0188","01530","03347","BK0028","688428","600160","01415","BK0196","159992","688235","01211","03750","BK0044","81211","06690","BK0229","09969","06613","600690","01801","BK0015","688099","03759"],"gpt_icon":0},{"id":"2552445110","title":"兴证全球基金谢治宇旗下兴全合宜A中报最新持仓，重仓小米集团-W","url":"https://stock-news.laohu8.com/highlight/detail?id=2552445110","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552445110?lang=zh_cn&edition=full","pubTime":"2025-07-20 18:14","pubTimestamp":1753006452,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日兴证全球基金旗下谢治宇薛怡然管理的兴全合宜灵活配置混合型基金(LOF)公布中报，近1年净值增长率36.12%。与上一季度相比，该基金前十大重仓股新增信达生物，诺诚健华，蓝思科技；其中小米集团-W持仓占比6.28%，为该基金第一大重仓股；高伟电子，腾讯控股，比亚迪股份等退出前十大重仓股；详细数据如下：","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250720182533a456c569&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250720182533a456c569&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1880383366.USD","LU1813983027.USD","81810","LU1868837565.USD","BK1523","LU0149721374.USD","LU0797268264.HKD","XIACY","BK1506","LU0039217434.USD","HXXD.SI","LU1961090484.USD","LU0918141705.HKD","LU1794554557.SGD","BK1607","LU0143863784.USD","LU0823426480.USD","LU0611395673.USD","BK1618","LU0823038988.USD","LU0051755006.USD","LU0320764599.SGD","LU0417516738.SGD","LU2097828631.EUR","BK1521","LU0326950275.SGD","LU0359201885.HKD","SG9999003461.SGD","LU0348735423.USD","LU2778985437.USD","BK1589","SG9999002463.SGD","LU2097828557.USD","LU0345775950.USD","LU2097828805.USD","LU0348827113.USD","LU2152927971.USD","MIUmain","LU0211977185.USD","LU1282648689.USD","SG9999001093.SGD","LU0823397103.USD","LU0164880469.USD","09969","LU0572944931.SGD","LU0823413660.USD","LU0588546209.SGD","LU1105468828.SGD","688428","01810","LU0359201612.USD","LU0345776255.USD"],"gpt_icon":0},{"id":"2552501464","title":"诺诚健华：因股份激励计划发行新股总计217.675万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2552501464","media":"公司公告","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552501464?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:55","pubTimestamp":1752828912,"startTime":"0","endTime":"0","summary":"诺诚健华公告，根据2023年人民币股股份激励计划，于2025年7月18日向董事及激励对象发行新股总计217.675万股，每股发行价为RMB6.95，占有关事件前的现有已发行股份比例合计为0.12%，包括首次授予及预留授予部分。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718171431a4531a29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718171431a4531a29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","09969","688428"],"gpt_icon":0},{"id":"2552120793","title":"诺诚健华-U股价微跌0.56% 创新药板块年内表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2552120793","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552120793?lang=zh_cn&edition=full","pubTime":"2025-07-17 03:24","pubTimestamp":1752693853,"startTime":"0","endTime":"0","summary":"截至2025年7月16日15时，诺诚健华-U股价报30.25元，较前一交易日下跌0.17元，跌幅0.56%。当日开盘价为30.39元，最高触及30.66元，最低下探至29.50元，成交量为84167手，成交金额达2.54亿元。诺诚健华-U属于生物制品和创新药板块。公司专注于肿瘤及自身免疫性疾病领域的创新药物研发，产品管线涵盖小分子药物和生物制剂。数据显示，诺诚健华-U当日主力资金净流出2397.76万元，占流通市值的0.3%。近期创新药板块表现活跃，年内整体涨幅超过36%，多只医药主题基金净值创出新高。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071703304197a8c8d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071703304197a8c8d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","BK0239","688428"],"gpt_icon":0},{"id":"2551114230","title":"大佬举牌Biotech龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2551114230","media":"瞪羚社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551114230?lang=zh_cn&edition=full","pubTime":"2025-07-15 20:04","pubTimestamp":1752581040,"startTime":"0","endTime":"0","summary":"上市公司大股东计划通过证券交易所集中竞价交易减持股份，应当在首次卖出的15个交易日前预先披露减持计划。2025年上半年，机构大佬通过举牌方式重仓创新药公司并非只有诺诚健华这一例。此外，其在血液瘤方面目前的王牌应该Bcl-2抑制剂——ICP-248。患者基线上，72.7%的患者为难治性疾病，56.4%的患者既往接受过BTK抑制剂治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507161248499544615c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507161248499544615c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","BK0239","09969"],"gpt_icon":0},{"id":"2551316414","title":"诺诚健华：2023年科创板限制性股票激励计划部分归属期完成股份登记并上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2551316414","media":"公司公告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551316414?lang=zh_cn&edition=full","pubTime":"2025-07-15 19:50","pubTimestamp":1752580234,"startTime":"0","endTime":"0","summary":"诺诚健华公告，公司已完成2023年科创板限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期的股份登记工作。本次归属涉及138名激励对象，归属股票数量为207.675万股，上市流通日为2025年7月18日。本次归属后，公司已发行股份总数增至176464.395万股，新增股份对公司财务状况和经营成果不构成重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715200109a44c5c78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715200109a44c5c78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","688428","09969"],"gpt_icon":0},{"id":"2551156152","title":"医保商保双目录调整 生物医药午后涨幅扩大 荣昌生物涨逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551156152","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551156152?lang=zh_cn&edition=full","pubTime":"2025-07-15 14:18","pubTimestamp":1752560315,"startTime":"0","endTime":"0","summary":"截至发稿，荣昌生物涨8.37%，石药集团涨7.26%，诺诚健华涨6.95%，百济神州涨6.43%，中国生物制药涨4.61%，信达生物涨3.66%。消息面上，2025年国家基本医疗保险，生育保险和工伤保险药品目录及商业健康保险创新药品目录调整7月11日正式启动。世纪证券指出，创新药商保目录意味着国内医药多元支付体系重构，商业健康险将在创新药支付方面扮演更为重要的角色，高价创新药可及性有望进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071514191497a6a43d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071514191497a6a43d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","IE00BZ08YR35.GBP","LU1226287875.USD","LU1226288253.USD","LU2328871848.SGD","IE0008369823.USD","BK1191","IE00B5MMRT66.SGD","LU0501845795.SGD","01801","BK1161","BK1515","LU0880133367.SGD","IE0008368742.USD","LU1969619763.USD","01177","LU0072913022.USD","SG9999004220.SGD","LU0067412154.USD","SBHMY","LU0140636845.USD","ONC","688428","IE00B031HY20.USD","LU1807302812.USD","688331","BK1521","LU1960683339.HKD","LU1152091168.USD","LU1951186391.HKD","688235","BK1574","LU1226287792.SGD","09969","09995","IE00B543WZ88.USD","LU1226288170.HKD","IE00BZ08YT58.USD","01093","LU1008478684.HKD","LU1152091754.HKD","LU0315179316.USD","LU1226287529.USD","LU0326950275.SGD","LU1993786604.SGD","06160","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2551130044","title":"港股异动 | 诺诚健华(09969)早盘涨超6% BCL2抑制剂Mesutoclax治疗AML和MDS在美国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2551130044","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551130044?lang=zh_cn&edition=full","pubTime":"2025-07-15 11:14","pubTimestamp":1752549242,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华早盘涨超6%，截至发稿，涨5.24%，报17.26港元，成交额1.94亿港元。消息面上，诺诚健华宣布，公司自主研发的新型BCL2抑制剂mesutoclax联合阿扎胞苷治疗髓系恶性肿瘤，包括急性髓系白血病和骨髓增生异常综合征，已获得美国食品药品监督管理局批准开展临床研究。Mesutoclax通过选择性地抑制BCL2，恢复肿瘤细胞程序性死亡机制，从而发挥抗肿瘤疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317801.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688428","BK1574","BK1161","09969"],"gpt_icon":0},{"id":"2551132160","title":"肿瘤治疗概念盘中拉升，南模生物涨4.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551132160","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551132160?lang=zh_cn&edition=full","pubTime":"2025-07-15 09:41","pubTimestamp":1752543666,"startTime":"0","endTime":"0","summary":"07月15日，肿瘤治疗概念盘中拉升，截至09点41分，肿瘤治疗概念整体指数上涨0.60%，报1589.070点。从个股上来看，该概念的成分股中，南模生物涨4.33%，安科生物、诺诚健华-U、上海谊众涨幅居前。从资金上来看，截止发稿，肿瘤治疗概念主力净流入为-3.03亿，其中安科生物受到资金热捧，主力净流入2816.20万；拉长时间线来看，该板块近20日主力资金净流入-56.26亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715094106a44b089b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715094106a44b089b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688265","688091","BK0216","688428"],"gpt_icon":0},{"id":"2551069929","title":"诺诚健华新型BCL2抑制剂Mesutoclax治疗AML和MDS在美国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2551069929","media":"诺诚健华INNOCARE","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551069929?lang=zh_cn&edition=full","pubTime":"2025-07-14 08:31","pubTimestamp":1752453068,"startTime":"0","endTime":"0","summary":"诺诚健华今天宣布，公司自主研发的新型BCL2抑制剂mesutoclax联合阿扎胞苷治疗髓系恶性肿瘤，包括急性髓系白血病和骨髓增生异常综合征，已获得美国食品药品监督管理局批准开展临床研究。Mesutoclax是一款新型口服高选择性BCL2抑制剂，BCL2是细胞凋亡通路的重要调控蛋白，其表达异常与多种恶性血液肿瘤的发生发展相关。Mesutoclax通过选择性地抑制BCL2，恢复肿瘤细胞程序性死亡机制，从而发挥抗肿瘤疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714084020a44887b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714084020a44887b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","688428","09969"],"gpt_icon":0},{"id":"2550983556","title":"港股异动 | 诺诚健华午后拉升涨超15%，ICP-B794近日获批临床，机构称公司未来催化剂丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2550983556","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550983556?lang=zh_cn&edition=full","pubTime":"2025-07-11 14:40","pubTimestamp":1752216004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华午后涨超14%，截至发稿，涨13.73%，报15.74港元，成交额5.92亿港元。消息面上，7月3日，诺诚健华宣布其自主研发的靶向B7-H3的新型ADC创新药ICP-B794获得国家药品监督管理局药品审评中心批准，可以开展临床研究。目前全球尚无B7-H3靶向疗法获批上市，诺诚健华这一创新成果具有先发优势。","market":"fut","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"91d34d061fab89b3d85741a1f245f72b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1316635.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK0239","BK1161","BK1574","688428"],"gpt_icon":0},{"id":"2550693607","title":"诺诚健华-U涨5.10% 医保政策利好叠加产品放量提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2550693607","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550693607?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:01","pubTimestamp":1752112908,"startTime":"0","endTime":"0","summary":"诺诚健华-U今日股价大幅上涨，截至10点01分，最新价为26.40元/股，涨幅达5.10%。资金博弈与估值分化驱动股价波动近期诺诚健华-U股价波动受多重短期因素交织影响。此外，2025年前三季度营收同比激增129.92%，核心产品奥布替尼商业化放量提振市场信心，但板块轮动导致医药生物指数7月7日单日下跌0.97%，存量资金腾挪进一步放大个股波动。创新管线突破与盈利兑现的平衡考验长期来看，诺诚健华的核心竞争力在于肿瘤治疗领域的前沿布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710100150a4416f4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710100150a4416f4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2550058575","title":"港股异动 | 诺诚健华(09969)涨近4% 近日宣布新型ADC创新药ICP-B794获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2550058575","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550058575?lang=zh_cn&edition=full","pubTime":"2025-07-09 10:29","pubTimestamp":1752028146,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华涨近4%，截至发稿，涨3.85%，报13.48港元，成交额7532.46万港元。消息面上，据诺诚健华官微消息，7月3日，诺诚健华宣布，公司自主研发的靶向B7-H3的新型ADC创新药ICP-B794获国家药品监督管理局药品审评中心批准开展临床研究。据介绍，ICP-B794是一款由人源化抗B7-H3单抗通过蛋白酶可裂解连接子与公司自主开发的强效有效载荷偶联而成。目前全球尚无B7-H3靶向疗法获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06978","688428","BK1161","159992","09969","BK4231","BK0239","BK4080","ADC"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753899689705,"stockEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.2403},{"period":"3month","weight":0.3918},{"period":"6month","weight":1.4938},{"period":"1year","weight":2.4083},{"period":"ytd","weight":1.4674}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0497},{"period":"3month","weight":0.1027},{"period":"6month","weight":0.1123},{"period":"1year","weight":0.2558},{"period":"ytd","weight":0.0788}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2022-09-21","address":"Ogier Global(Cayman)Limited 89 Nexus Way Camana Bay Grand Cayma KY1-9009 Cayman Islands","registeredCapital":"0万元","survey":"　　诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、研发服务。公司获得奖项为中国技术创业协会科技创新贡献奖、北京市“专精特新”中小企业、中国新经济企业500强等。2023年获得国家级专精特新“小巨人”企业荣誉。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}